VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture (“JV”, “MML”) has expanded its technical team to support the next phase of development of MIDS Cardiac.
Following its recent funding agreement MML has arranged the services of three key contractors for its next phase of MIDS development. These contracting arrangements are designed to efficiently obtain services as and when required by MML.
The Magnetism Group at the University of Liverpool led by Dr Liam O’Brien, lecturer at the University of Liverpool and a member of the Condensed Matter Physics group and Materials Innovation Factory, will assist MML in the calibration and development of its medical diagnostic technologies. Dr O’Brien’s experience includes spatially-resolved Kerr effect microscopy, magnetic nanostructures, thin film magnetic materials, and spintronic devices and will be used to assist MML with microfluidic design in conjunction with its established technical design consultants. This is expected to include the computer simulation of microfluidic and magnetic bias field instigated flow of fluids and assay beads within the MIDS microfluidic strip prior to manufacture, and verification of built specification once manufactured.
Magnetism Group leader Dr O’Brien commented: “MIDS next generation technology offers exciting prospects in point-of-care diagnostics. We look forward to working with their team. This is an ideal opportunity to use our expertise in nanoscale magnetic materials characterisation to assist Dr Djennati and his team in the development of MML medical devices.”
MML has also arranged the services of two independent electronics engineers with a combined and complementary experience of over fifty years in the electronic disciplines demanded by the MIDS project. This includes embedded digital and analogue hardware and software design, multilayer PC design, immunoassay and magnetic particle experience, control systems and data acquisition.
About Zenosense, Inc.
Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.zenosense.com
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.
Tel: +34 960 454 202